Key Words: Pim-1 Ⅲ bone marrow cells Ⅲ myocardial infarction Ⅲ myocardial structure Ⅲ hypertrophy C ardiovascular disease leading to myocardial infarction (MI) affects a large population, with occurrence of acute coronary blockage causing irreversible myocardial damage, morbidity, and mortality. Due to the limited regenerative capacity of the heart after injury, 1 sustained cardiomyocyte damage and myocyte loss contribute to increases in infarct size, decreased cardiac function, and the development of heart failure. In the past decade, cell-based therapeutic treatment to mitigate MI injury has been investigated with a variety of adult stem cells. Bone marrow-derived cells (BMCs) have been a popular choice due in part to easy availability, proven safety, and efficacy in the clinical setting. BMCs promote repair of infarcted myocardium via mobilization of actively proliferating stem and progenitor cells after cytokine stimulation. 2 As a result, BMC therapy to mitigate heart failure has been attempted with unfractionated BMCs as well as selected constituent populations derived from bone marrow including mesenchymal stem cells, 3,4 endothelial progenitor cells, 5 very small embryonic-like stem cells, 6,7 and lineage negative c-kit positive hematopoietic stem cells (Lin Ϫ /c-kit ϩ ). 8, 9 Heterogeneous BMC preparations and individual subpopulations impart beneficial repair to the damaged myocardium, 10,11 although consensus as to the optimal cell population(s) to enact BMC-mediated repair remains elusive. Regardless of cell type used, persistence is relatively poor and the majority of delivered cells are rapidly lost. 12 Mechanistically, promotion of endogenous repair is thought to involve paracrine dependent action of a secretome, 13 
C ardiovascular disease leading to myocardial infarction (MI) affects a large population, with occurrence of acute coronary blockage causing irreversible myocardial damage, morbidity, and mortality. Due to the limited regenerative capacity of the heart after injury, 1 sustained cardiomyocyte damage and myocyte loss contribute to increases in infarct size, decreased cardiac function, and the development of heart failure. In the past decade, cell-based therapeutic treatment to mitigate MI injury has been investigated with a variety of adult stem cells. Bone marrow-derived cells (BMCs) have been a popular choice due in part to easy availability, proven safety, and efficacy in the clinical setting. BMCs promote repair of infarcted myocardium via mobilization of actively proliferating stem and progenitor cells after cytokine stimulation. 2 As a result, BMC therapy to mitigate heart failure has been attempted with unfractionated BMCs as well as selected constituent populations derived from bone marrow including mesenchymal stem cells, 3, 4 endothelial progenitor cells, 5 very small embryonic-like stem cells, 6, 7 and lineage negative c-kit positive hematopoietic stem cells (Lin Ϫ /c-kit ϩ ). 8, 9 Heterogeneous BMC preparations and individual subpopulations impart beneficial repair to the damaged myocardium, 10, 11 although consensus as to the optimal cell population(s) to enact BMC-mediated repair remains elusive. Regardless of cell type used, persistence is relatively poor and the majority of delivered cells are rapidly lost. 12 Mechanistically, promotion of endogenous repair is thought to involve paracrine dependent action of a secretome, 13, 14 with transdifferentiation playing a very limited role in formation of functional myocardium. Although safety of BMC delivery has been validated in the clinic, [15] [16] [17] [18] efficacy remains disparate among different studies and the salutary effects of BMC transplantation for the heart after injury are modest, falling short of what would be needed to restore normal contractility.
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The serine/threonine kinase Pim-1 promotes cell proliferation and survival and regulates aspects of cellular metabolism and transcriptional activity. 19 -21 Enhancement of stem cells to improve regenerative capacity is a proven successful strategy in experimental animal models. Molecular engineering to increase cell survival, proliferation, and augmentation of endogenous repair has been achieved with a number of interventional approaches. [22] [23] [24] Our group recently demonstrated that lentiviral-mediated Pim-1 kinase overexpression in cardiac progenitor cells (CPCs) increases survival and promotes efficient differentiation into cardiogenic lineages needed to sustain improvements in myocardial structure and function. 25 Mechanistically, Pim-1 improves regeneration by enhancing resistance to apoptosis 26 and increasing cell cycling. 27 Thus, expression of Pim-1 ex vivo is a promising approach to advance the application of BMC-based cell therapy in vivo.
Growth factor delivery after MI promotes acute reparative responses by activation of endogenous stem cells, protection of cardiomyocytes, and induction of protective signaling pathways in rodent models. 28, 29 However, the limited success of growth factor delivery in human clinical trials has turned the focus to stem cell-based therapies to perform similar paracrine effects within the myocardium. 30 Benefits from BMC delivery include improved metabolic activity, 31 reduced inflammation and fibrosis, 32 and reactivation of the fetal gene program to sustain live myocardium after myocardial damage. 33 Genetic modifications of stem cells enhance the therapeutic capabilities of BMCs by modulating transcription, changing paracrine profiles, and directing cellular fate. 24, 31 Pim-1 has been shown to promote similar effects on transcription in the heart as well as in distinct cell populations. Pim-1 augments cytokine production via the NF-B pathway and induces expression of NFATc1, promoting cellular differentiation. 34 Therefore, it becomes important to investigate the differential effects of Pim-1 overexpression in BMCs to activate survival and hypertrophic pathways in heart tissue to mitigate myocardial damage relative to nonmodified BMCs.
Genetic modification through the use of lentiviral-based gene delivery systems has been utilized in BMC-based studies, 25, 35 yet the application of Pim-1 kinase for modification of a c-kit ϩ BMC has not been used as a modality of stem cell protection after myocardial delivery. Findings presented in this study reveal distinct properties of Pim-1-modified BMCs (BMCeP) to promote myocardial repair after delivery into the infarcted myocardium compared with BMCs modified with green fluorescent protein (GFP) alone (BMCe). BMCeP-treated hearts display acute salvaging of the myocardium, which prevents scar formation and concomitant reduction in infarct size. Therefore, this study describes the therapeutic advantages of BMCeP to blunt the progression of pathological remodeling that inevitably accelerate the onset of heart failure.
Methods
An expanded Methods section is available in the Online Data Supplement.
BMC Culture and Lentiviral Transduction
C-kit ϩ cells were isolated from whole bone marrow extracted from young male mice of the Friend leukemia Virus B strain using magnetic activated cell sorting and plated in full-growth media (see Online Supplement for full details). BMCs were transduced with lentiviruses as previously described for CPCs, 25 with additional details provided in the Online Supplement.
Trypan Blue Exclusion Assay, MTT Assay, and Cell Proliferation Assay
Cell numbers were determined by trypan blue staining to exclude nonviable cells and immediately placed in 96-well microplates with 100 L of full-growth media. Additional methods for these assays are provided in the Online Supplement.
Cell Death Detection
Apoptotic cell death assay using a photometric enzyme immunoassay (Cell Death Detection ELISA PLUS , Roche Applied Science) for detection of histone-associated DNA fragments was performed on BMCs plated in duplicates of 10 000 cells in a 96-well microplate and treated with 10 mol/L and 20 mol/L tert-Butyl hydroperoxide solution (Sigma) in 200 L of full growth media for 16 hours. Measurements and quantification of the assay are provided in the Online Supplement.
MI Surgery, Echocardiography, and Hemodynamics
Animal model surgeries, performance of echocardiography, and in vivo hemodynamics were performed as previously described, 25 with further description in the Online Supplement.
Statistical Analysis
Statistical analysis was performed using Prism software. Graphical data are represented as meanϮSEM. The Student t test was used when comparing 2 experimental groups, and 1-way ANOVA followed by a Tukey post hoc test was calculated when more than 2 groups were being analyzed. Echocardiography assessment was analyzed using repeated-measures 2-way ANOVA followed by a Bonferroni post hoc test. A probability value Ͻ0.05 was considered statistically significant.
Animals
All animal experiments were performed in accordance with protocols approved by the San Diego State University Institutional Animal Care and Use Committee.
Results

Characterization of c-Kit
؉ BMCs for Pim-1 Kinase, Phenotypic Properties, and Cytokine Expression BMCs were transduced using bicistronic lentiviral constructs (Online Figure I , A) and passaged 8 times in a 96-well microplate to efficiently integrate transgene(s) and create stable cell lines. BMCs expressing enhanced GFP (eGFP) are referred to as BMCe, whereas cells overexpressing human Pim-1 kinase in combination with eGFP are designated as BMCeP. Expression of the exogenous Pim-1 transgene in BMCeP as well as the presence of eGFP in both BMCe and BMCeP populations was confirmed by immunoblot (Online Figure I, B) . Expression of eGFP and the membraneassociated stem cell marker c-kit were verified by flow cytometry (Online Figure I , C and D) and immunohistochemistry ( Figure 1A and 1B) in BMCe and BMCeP populations, demonstrating that BMCs were effectively modified to express GFP and Pim-1 kinase.
C-kit, sca-1, CD45, and CD31 are highly expressed in BMCs after flow cytometric analysis ( Figure 1C ). Mature hematopoietic markers for T cells, B cells, or erythrocytes were not prominently expressed in BMCe and BMCeP ( Figure 1C ). Consistent with increased acquisition of the myeloid progenitor marker CD34 in BMCe, the nonenhanced BMC population revealed increased expression of Mac-1, Gr-1, and mesenchymal stem cell marker CD90.1 compared with BMCeP ( Figure 1C ). Collectively, these results indicate that Pim-1 overexpression in BMCs promotes an enriched stem cell population of the hematopoietic origin that is unadulterated by mesenchymal stem cell populations after long-term culture. Expression profile of cytokines was determined by a mouse-specific cytokine and inflammation PCR array in engineered BMCs and CPCs (Online Figure II , A through C, and Online Supplement Results for full description).
Pim-1 Increases Proliferation and Reduces Apoptosis in BMCs
BMCeP cell number is significantly increased relative to BMCe at day 5 (PϽ0.01) and day 7 (PϽ0.01) in culture ( Figure 2A ). Furthermore, metabolic activity is increased in BMCeP compared with BMCe at day 3 (PϽ0.001) and day 6 (PϽ0.001) ( Figure 2B ). BMCeP proliferation is enhanced compared with BMCe at day 5 (PϽ0.01) and day 7 (PϽ0.001), as confirmed by a direct nuclear stain ( Figure  2C ). Antiapoptotic protein Bcl2-␣ expression is 2.5-fold higher in BMCeP relative to BMCe (PϽ0.0001) ( Figure 2D ), consistent with previous results. 36 Bcl-2␣ expression is not significantly increased in BMCeP maintained in full growth media (Online Figure III, A) . Therefore, before protein analysis, cells were subjected to growth factor withdrawal of cytokines for 72 hours to downregulate endogenous Pim-1 in BMCe 37, 38 (Online Figure III, C) . However, we recognize that cytokine independence in vitro does not recapitulate an acute MI, an environment that has the potential to supply cytokines to activate prosurvival signaling in delivered BMCs. 39, 40 BMCeP display reduced apoptosis by measurement of fragmented nucleosomes in the cytoplasm compared with BMCe after treatment with the oxidative stress agent hydrogen peroxide H 2 O 2 at 10 mol/L (Pϭ0.02) and 20 mol/L (Pϭ0.04) ( Figure 2E ). However, basal apoptosis in nontreated BMCe and BMCeP was not significantly different (Online Figure III, B) . The data indicate enhanced proliferation and reduction of apoptotic cell death in BMCeP.
Myocardial Structure Is Improved in BMCeP Hearts
Cardiac structure and performance was assessed by echocardiography up to 18 weeks after injection of BMCs or vehicle into the border zone (BZ) immediately after left anterior descending artery ligation. Decreased ejection fraction (EF) ( Figure 3A , 3E, and 3F), chamber volume dilation ( Table I) were verified 1 week after infarction. However, posterior wall thickness (PW;d) was not affected by left anterior descending artery ligation or long-term infarction in sham-operated and experimental groups (Online Figure IV, A) . EF is significantly increased in hearts receiving BMCeP (PϽ0.001) ( Figure 3A ) compared with PBS treatment at 4 weeks after injection. Hemodynamic performance was improved in BMCeP-delivered hearts compared with both PBS-treated (PϽ0.01) and BMCe-treated (PϽ0.05) ( Figure 3B ) hearts 12 weeks after infarction. Additionally, prevention of left ven- tricle dilation up to 18 weeks after surgery ( Figure 3C and 3D) compared with PBS-injected groups was observed. Anterior wall (AW) thickness among the treated heart groups was not significantly different (Online Figure IV , B) when measurements were taken directly in the area of the infarct. However, AW thickness of the neighboring BZ was increased in BMCeP-delivered hearts compared with PBS (PϽ0.01) and BMCe (PϽ0.01) ( Figure 3E ) at 4 weeks after infarction and maintained this effect up to 12 weeks after infarction compared with PBS alone. The relative percentage of akinetic left ventricular wall was decreased in BMCeP-treated hearts at 4 and 12 weeks after infarction compared with PBS-treated (PϽ0.001) and BMCe-treated (PϽ0.001) groups (Online Figure IV , C). These results were corroborated at 12 weeks after infarction as the percentage of the left ventricular free wall was greatly reduced in BMCeP hearts compared with PBS-treated groups (Pϭ0.004) and BMCeP relative to BMCe-injected hearts (Pϭ0.02) ( Figure 3F ). These results indicate that long-term introduction of BMCeP supports modest improvements in EF and hemodynamic performance, increases in AW thickness, and enhanced preservation of the myocardium by reducing the formation of scar and infarct size (values and sample sizes in Online Table I ).
Enhanced Persistence and Recruitment of Endogenous c-Kit ؉ Cells in BMCeP Hearts
Endogenous c-kit Figure 4H ). In summary, BMCeP-treated hearts exhibit the highest level of cellular persistence and recruitment of donated and endogenous populations, respectively, which may be due to enhanced paracrine secretion of LIF.
Protective Effects of BMCeP as Evidenced by Increased Cellular Hypertrophy in the Damaged Region
Cross-sectional myocyte size in the BZ and infarcted (IZ) regions is increased in BMCeP-injected (BZ PϽ0.0001, IZ PϽ0.0001) and BMCe-injected (BZ PϽ0.05, IZ PϽ0.0001) hearts relative to the PBS group ( Figure 5B and 5C). Myocyte hypertrophy in BMCeP-injected hearts is significantly greater in the BZ region and the infarcted regions compared with BMCe (BZ PϽ0.05, IZ PϽ0.05) ( Figure 5B and 5C), but cardiomyocyte size was not affected in BMC injected hearts relative to sham controls in the remote region ( Figure 5A ; BMCe, Pϭ0. 24 and BMCeP, Pϭ0.17) . Decreases in myocyte size in the remote regions of PBS injected hearts are probably a consequence of accelerated progression into heart failure ( Figure 5A ; sham Pϭ0.02, BMCe, Pϭ0.03 and BMCeP, Pϭ0.07). Localized cardiomyocyte hypertrophy resulting from BMCeP treatment is distinct from the protective effects mediated by Pim-1 overexpressing CPCs (CPCeP) as treatment revealed increases in small myocytes in the damaged regions consistent with enhanced regenerative response up to 12 weeks without increased cardiomyocyte hypertrophy (Online Figure VII) . 25 BMCeP-treated hearts had increased heart weight-to-body weight ratios (HW/BW) from sham controls at 12 weeks (Pϭ0.04) (Online Figure VIII and Online Table  II ). However, HW at 12 and 18 weeks and HW/BW ratios at 18 weeks in infarcted groups were significantly increased from sham animals comparably. In conclusion, increased localized cardiomyocyte size in BMC-treated hearts does not significantly alter heart weight relative to PBS-treated controls.
Cardiomyocyte Hypertrophic Signaling Is Induced by BMC Delivery
Compensatory hypertrophy in cardiomyocytes in response to MI has been reported in animal models as evidenced by induction of fetal hypertrophic markers. 33 Perinuclear expression of ANP is increased in BZ cardiomyocytes in hearts receiving BMCeP and BMCe, whereas ANP expression is reduced in the perinuclear space after PBS treatment (Online 42 and genes to regulate hypertrophy. 43 
Discussion
Cellular therapy for treatment of acute MI is gaining acceptance as a safe and efficacious approach to enhance hemodynamic function from experimental studies 8, 44 and clinical trials. 45 Spearheaded by adult stem cells derived from either cardiac or bone marrow sources, the field has begun the laborious task of defining the optimal cell type to promote cellular cardiomyoplasty and the technical refinements required to augment effi- cacy without compromising safety. However, substantial variations in preparation of cell type, implementation of treatment protocol design, assessments, and resultant outcomes have obscured straightforward conclusions of the biological superiority of bone marrow-derived versus cardiacderived stem cells for treatment of infarction injury. 46 The stem cell marker c-kit was previously used by our group as a selection marker to enrich for CPCs with regenerative properties enhanced by genetic engineering with Pim-1 kinase. 25 Therefore, an identical strategy was implemented to determine whether prior findings with CPC could be reproduced using BMCs. Genetic engineering with Pim-1 kinase remains a valid approach to improve the reparative potential of c-kit ϩ cells. Fundamentally distinct effects are mediated by BMCs as presented in this study when compared with our previous CPC-based results. 25 Evidence of hematopoietic cell transdifferentiation into specialized epithelial cells and skeletal myocytes supported interest in the bone marrow as a source of stem cells to repair physiological damage. 47 Studies of Lin Ϫ /c-kit ϩ BMCs in the heart were additionally reported to adopt cardiogenic fates after cytokine stimulation and adoptive transfer following MI. 8, 9 Despite the initial optimism of BMC therapy to directly repair damaged tissue, contradictory findings have called into question the plasticity of hematopoietic cells. 48 We acknowledge that adequate differentiation of BMCs remains a challenge, and this may be due in part to differences in isolation, expansion, and genetic priming of stem cells among research groups. To delineate conflicts among existing reports, BMCs were treated ex vivo similar to CPCs, yet they remained undifferentiated in vivo. Prudent characterization of BMCe and BMCeP revealed unique properties within hematopoietic cells that have not been previously reported. Genetically modified BMCs were subjected to long culture conditions, a comparatively rare practice before intramyocardial injection. This protocol allowed us to identify a distinct population influenced by Pim-1 overexpression, decreasing the presence of contaminating mature hematopoietic markers and mesenchymal stem cells ( Figure 1C) . Therefore, our exclusive findings present that long-term introduction of Pim-1 in BMCs defines a novel cell population to enhance long-term structural benefits in the heart (Figure 3) . Regardless of stem cell type used for adoptive transfer therapy, substantial cell death after transplantation into the infarcted heart is a significant limitation to initiate repair. 49 Using the same lentiviral-based genetic engineering strategy that successfully improved CPC persistence and engraftment, BMCeP showed increased resistance to oxidative stress and increased proliferation (Figure 2 ) similar to CPCeP properties. 25 Although intrinsic survival and expansion of the BMC population is improved by Pim-1 engineering, the survival of BMCeP in the ischemic myocardium required validation. In vivo persistence of BMCeP ( Figure 4G ) was increased relative to delivery of BMCe, subsequently confirmed by coexpression of CD45 and GFP (Online Figure V , B and C), indicating that BMCe and BMCeP retain their hematopoietic marker despite long-term viability in the infarct. Increased cellular engraftment appears to be a direct consequence of preserved BMC survival as Pim-1 plays an integral role in preserving mitochondrial health contributing to decreased DNA damage and cellular death in the face of acute inflammation and oxidative stress. These attributes are important to preserving BMC integrity; however, our study is limited to an observation of long-term persistence after infarction, as heart samples were not analyzed during the acute stage after MI. The increased presence of BMCeP augmented recruitment of endogenous c-kit cells in the infarcted region well after infarction challenge (Figure 4 ) similar to previous reports. 28,44,50 -53 Prior analysis of CPCeP supported positive left ventricular remodeling without affecting the total number of c-kit ϩ cells. 25 This concludes that Pim-1 similarly influences the survival of BMCs and CPCs, yet the fate of CPCs is most consistent with cardiogenic differentiation 25 and points to a potential paracrine role in BMCs to enhance myocardial repair.
Cardiac specific expression of Pim-1 antagonizes adverse remodeling after pathological stress. 26, 54 Although Pim-1 expression has been observed to negate cardiomyocyte hypertrophic growth, 54 the role of Pim-1 in non-cardiac-derived stem cells for adoptive transfer has not been investigated. Increased survival of delivered BMCeP is influential to determining a connection between paracrine secretion and observed myocardial structural remodeling. Noticeable physiological effects include localized cellular hypertrophy, a BMC-dependent mechanism, as we analyzed 12-week CPCinjected hearts and observed no effect on cardiomyocyte size in the BZ (Online Figure VII) . Similarly in a pressure overload model, hypertrophy was observed after delivery of BMCs from young mice, preventing progression into heart failure. 33, 55 Protein expression of ANP was visualized in the perinuclear space of cardiomyocytes as previously reported 56 and increasingly detected in BMCeP-and BMCe-treated hearts relative to PBS (Online Figure IX) . Attenuated myocardial hypertrophy was observed in transgenic mice express- ing nuclear targeted Akt in cardiomyocytes due to increased ANP expression, yet BNP was not significantly altered. 56 Exogenous delivery of natriuretic peptides reduce hypertrophy 57 and decrease adverse remodeling after MI. 58 These studies suggest that ANP does not promote hypertrophy but is expressed during hypertrophic development to inhibit pathological progression. 56 Although ANP is increased in our BMC-treated hearts, cardiomyocyte hypertrophy may be regulated by induction of other hypertrophic genes such as BNP, which is increased significantly in BMCeP hearts (Online Figure IX, E) .
As demonstrated in this report, 14 cytokine genes were differentially expressed in BMCeP compared with BMCe. Additionally, CPCeP were subjected to the exact array to determine contrasting production of cytokines relative to CPCe and BMCeP (Online Figure II, C) . For example, IL-6 family member of cytokines, LIF, CT-2, and IL-11 influence cardiomyocyte growth by activation of STAT3 (Online Figure II, A and B, and Figure 4H ) 59 factors that were not increasingly detected in CPCeP. Additionally, BMP proteins (Online Figure II, A and B) , promote hypertrophy and myocardial remodeling by phosphorylation and activation of SMAD2 after MI 60 a potential BMP-dependent mechanism of observed cardiomyocyte hypertrophy in BMC-treated hearts. Activation of STAT3 43 has been previously reported as a compensatory hypertrophic molecule in the instance of myocardial damage, however, combined chronic levels of LIF and IL-6 expression contribute to global hypertrophy and heart failure. 61 In our system, elevated levels of LIF were not detected in our injected heart groups (data not shown), and HW and HW/BW were not significantly altered among infarcted heart groups (Online Figure VIII) , suggesting the absence of adverse inflammation and pathological hypertrophy. In fact, we have data to suggest that BMCeP secretes anti-inflammatory factors IL-21 and decreased production of the proinflammatory factor IL-1␣ compared with BMCe (Online Figure II, A and B) . However, paracrine secretion observed in vitro is only correlative to induce cardiomyocyte hypertrophy after adoptive transfer. To explain reduced akinesis (Online Figure IV) and increased AW;d thickness ( Figure 3E ) as early as 4 weeks after infarction, it is postulated that prohypertrophic factors secreted by BMCs in the BZ and infarcted regions in the acute phase of MI were driving forces of localized cardiomyocyte hypertrophy by activation of SMADs and STAT3 signaling cascades, but this cannot be confirmed within the long-term time frame of our experiment.
Pim-1 genetic modification of BMCs to improve survival and resistance to apoptosis in the myocardial infarct is a revolutionary concept to treat the acute adverse effects of cardiovascular disease. Direct comparison of BMCeP versus CPCeP after myocardial delivery in the pathological heart reveals unique BMC-dependent mechanisms of myocardial repair. Previously from our group, we demonstrated the enhanced regenerative potential of CPCeP to directly replace cellular components of the damaged myocardium and significantly improve cardiac function relative to nonengineered cells. 25 Distinct properties of BMC to effect infarct reduction, recruitment of endogenous stem cells, and hypertrophy suggest that complementary synergistic actions may result from combined dual stem cell treatment with BMCeP and CPCeP. The new era of cell therapy to treat heart damage may benefit from the new mechanistic insights that Pim-1-modified BMCs have produced and presents a clinical option to effectively improve myocardial structure and prevent heart failure.
Novelty and Significance
What Is Known?
• The delivery of bone marrow cells (BMCs) after myocardial infarction (MI) confers modest improvements in cardiac function and supports beneficial cardiac remodeling.
• The applications of stem cell therapy is hindered by poor survival of transferred cells, limiting beneficial repair.
• Bone marrow-derived cells secrete paracrine factors to promote survival and differentiation of cardiac cells in the myocardium.
• Gene transfer of Pim-1 to cardiac progenitor cells (CPCs) increases cell cycling and asymmetrical division in vivo, providing a mechanism of enhanced regeneration after MI.
What New Information Does This Article Contribute?
• Pim-1 overexpression in BMCs (BMCeP) supports a unique stem cell population that exhibits enhanced proliferation and protection from oxidative stress.
• BMCeP delivery preserves myocardial structure for 12 weeks after infarction injury, contributing to the repair of the anterior wall and prevention of left ventricular dilation.
• Transfer of BMCeP cells into the heart contributes to increases in cardiomyocyte size and induction of hypertrophic genes.
Treatment of myocardial damage using adult stem cells from the bone marrow is a safe and efficacious choice validated in experimental models and clinical trials. However, BMC-based interventional approaches are limited due to poor survival, proliferation, and engraftment of delivered cells. Therefore, we established a genetic modification strategy to enhance BMC properties by overexpressing the prosurvival molecule Pim-1. BMCeP presented a unique cellular profile by enhancing stem cell phenotypic characteristics, beneficial paracrine secretion, and survival and proliferation in vitro. Adoptive transfer of BMCeP during acute MI highlighted the superior effects of these cells in preserving the structural integrity of the myocardium and reducing the formation of fibrotic scarring as early as 4 weeks after MI. BMCeP stimulated an increase in cardiomyocyte size in the border zone and the infarcted regions to prevent left ventricular dilation. These results support the therapeutic efficiency of Pim-1 in adult stem cells and contribute to the progress of future applications of BMCs to prevent heart failure.
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Supplemental Material
Supplemental Results Cytokine Expression of BMCeP and CPCeP in vitro
Expression profile of cytokines of the tumor growth factor (TGF-β) and the tumor necrosis factor (TNF) superfamilies was determined by a mouse specific cytokine and inflammation PCR array in BMCs (Supplemental Figure IIA) . Cytokines that influence embryonic cardiac development, post-natal hypertrophic growth and cardiac differentiation such as Bmp1 (4.5), Bmp10 (7.7), Bmp2 (2.0) and Growth differentiation factor 5 (Gdf5) (3.0) mRNA are up regulated more than two-fold in BMCeP compared to BMCe [1] [2] [3] [4] [5] [6] . IL-6 family member factors implicated in cardiac protection and cardiomyocyte hypertrophy, Interleukin-11 Figure IIC) . In summary, BMCeP display a cytokine expression profile gene favoring cardiac protection and growth while opposing adverse inflammation. 
Supplemental Methods Lentiviral constructs, production, and infection
Lentiviral transduction of BMC was performed using a bicistronic construct overexpressing either 1) the human Pim-1 gene and enhanced green fluorescence protein (eGFP) driven off a vIRES (BMCeP) or 2) the eGFP alone driven off a vIRES (BMCe). Protein expression was under control of a myeloproliferative sarcoma virus LTR-negative control region deleted (MND) promoter. Infection of c-kit+ enriched BMCs by the bicistronic lentivirus Lv-egfp or LveGFP+Pim-1 was performed with a multiplicity of infection (MOI) of 50 in the presence of Polybrene (4µg/ml) to facilitate lentiviral transduction. Cells were allowed 48 hours to express the eGFP reporter gene and human Pim-1, and then infected again with a MOI of 25.
Bone marrow cell isolation, culture and transduction with lentiviral constructs
BMCs were isolated from 8-15 week old FVB mice by flushing the femur and tibia with 5% FBS/PBS. Mononuclear cell layer from bone marrow was obtained using Histopaque (Sigma). Cells were labeled with anti-CD117 magnetic antibodies (Miltenyi Biotec), sorted for CD117 using MACS columns (Miltenyi Biotec), and cultured in 96-well round bottom plates at 1.5 X 10^5 cells per well in full media consisting of Stemspan (Stem Cell Technologies) supplemented with cytokines IL-3, IL-6, TPO at 20ng/mL and Flt3 ligand and H-SCF at 100ng/mL (Peprotech).
Trypan blue exclusion Assay
For trypan blue exclusion assay, cells were plated in quadruplicates of 10,000 cells per well. The number of viable cells (visibly bright cells) were counted based on exclusion of trypan blue dye up to 7 days.
MTT assay
Metabolic activity was determined using MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) (Sigma) in a colorimetric reducing assay wherein the yellow tetrazole is reduced to a purple formazan in living cells. 5,000 cells/100µL of complete media were plated per well in a 96-well flat bottom plate and given 10µL of 5mg/mL solution of MTT reagent for four hours and then incubated with 100µL (diluted HCL for lysis) of stopping reagent overnight. MTT assay was performed 1,3,6 days after plating and absorbance was read at 595nm in order to determine relative metabolic activity of cells at given days.
CyQUANT Direct Cell Proliferation Assay
Cell proliferation was determined by plating BMCe and BMCeP in quadruplicates of 5,000 cells/100µL of complete media per well in a 96-well flat bottom plate. Assay was initiated by incubation of each well in 100µL of CyQUANT (Invitrogen) green fluorescent nucleic acid stain and background suppression dye (to exclude non-living cells stained in the assay) diluted in PBS for 60 min. Green fluorescence intensity was measured at 495nm using a plate reader and represented as a fold change to the fluorescence intensity measured on the day of plating (day 0). Subsequent incubations and measurements were determined at days 1, 3, 5 and 7 after plating.
Induction and analysis of Bcl-2α expression in BMCs
Cell apoptosis/death was assessed following culture of 150,000 cells in 96-well plates containing full media or media lacking growth factors for 72 hours. Cells were harvested, washed twice in PBS with spinning at 1200rpm for 5 minutes to pellet the cells, and then resuspended in buffer containing reducing agents, protease and phosphatase inhibitors to create immunoblot lysates. 
Cell
Flow Cytometry
Cells were counted and placed in samples of 2.0 X 10 5 per tube, washed two times in 1% FBS/PBS, and then incubated with conjugated antibodies for 15 minutes at room temperature in a total volume of 100uL. After incubation cells were washed two times with 1% FBS/PBS and re-suspended in minimal amount of buffer for analysis using the FACSARIA (BD Biosciences). Antibodies were used at a concentration of 1ug for 2.0X10^5 cells. Conjugated Antibodies: C-kit (CD117) PE, APC (BD Biosciences), sca-1 PE (BD Biosciences), CD4 PE (BioLegend), CD8 (BioLegend), CD31 PE (BD Biosciences), CD34 RPE (BD Biosciences), CD45 APC (BD Biosciences), CD90.1 (BioLegend), CD90.2 PE (BioLegend), Ter119 PE (BioLegend), Mac-1 PE (BioLegend), Gr-1 PE (BioLegend), and B220 PE (BioLegend).
Immunohistochemistry: Fixed Cell Staining
BMCs were placed in minimal volume on glass slides and allowed to dry for two hours. Cells were then fixed in 4% paraformaldehyde for 30 minutes then washed in phosphate buffered saline. Cells were blocked in 10% horse serum/PBS for one hour and then incubated with primary antibodies overnight. Next day, cells were washed in PBS and incubated with corresponding secondary antibodies for 1.5 hours. Cells were washed in PBS followed by a final wash containing TO-PRO-3 iodide (Invitrogen) for 10 minutes to stain for nuclei. Primary antibodies used: goat anti-ckit (R&D systems 1:50), rabbit anti-GFP (Invitrogen 1:50).
Myocardial Infarction and Cell Injections
Ten-week old female FVB mice were subjected myocardial infarction carried out under isoflurane anesthesia by tying off the left anterior descending artery (LAD). After infarction injury, injections with either PBS (5µL per injection 5 injections total per mouse) or genetically enhanced cells (20,000 cells per 5 µL injection, 5 injections making a total of 100,000 cells injected per mouse) were introduced to the pre-ischemic border along the infarcted region. Sham operations were performed by opening and closing the chest.
Retroperfusions
Mice were sacrificed under chloral hydrate sedation. Before the procedure of removing the hearts, mice were weighed in grams. Thereafter, hearts were arrested in diastole by catheterizing the abdominal aorta and flushing the heart with a high-potassium/cadmium solution. Phosphate buffered formalin fixative was perfused into the coronary arteries at systolic pressure while the left ventricle was filled with formalin at diastolic pressure. Retroperfused hearts were then removed from the chest cavity and placed in formalin for at least 24 hours, weighed in milligram and processed for paraffin embedding.
Immunohistochemistry: Parraffin Sections
Heart sections were deparaffinized, and antigen was retrieved in 1 mmol/L citrate (pH 6.0), quenched in 3% H 2 O 2 /1X TN and blocked in TNB. Primary antibodies were incubated overnight at 4°C at appropriate dilutions. Slides were washed in 15mM NaCl/100mM Tris pH 7.5 (TN buffer) followed by secondary antibody incubation for two hours at room temperature. Subsequent tyramide amplification was performed as necessary. Cells were washed after secondary antibodies in TN followed by a final wash containing TO-PRO-3 iodide for 10 minutes to stain for nuclei. Primary antibodies used: goat anti-ckit (R&D Systems 1:100), rabbit anti-GFP (Invitrogen 1:500), mouse anti-tropomyosin (Sigma 1:100), rabbit anti-ANP (Peninsula Labs, 1:100), rat anti-CD45 (BD Biosciences 1:30). C-kit, GFP and CD45 required tyramide amplification protocols.
C-kit Cell Quantitation
Paraffin sections were probed with primary antibodies for c-kit and GFP. Nuclei were visualized using TO-PRO-3 iodide. C-kit+ and GFP negative, C-kit+ and GFP positive cells were scored only in the infarcted regions. Numbers of positive cells fitting each category were normalized to the area of infarction was determined using an outlining tool supplied by the Leica Imaging software. 12 week sections had an n=3 per group. 18 week sections had an n=4 per group.
Infarct size measurements
Paraffin sections were stained with tropomyosin to visualize live myocardium and TO-PRO-3 iodide to determine nuclei distribution and area of infarction. Area of live myocardium was measured using an outlining tool supplied by the Leica Imaging software and normalized to the total area of the left ventricular free wall and converted to a percentage. 12 week sections had an n=3 per group.
Myocyte size measurements
Paraffin sections were stained for tropomyosin to visualize live myocardium wheat germ agglutinin-488 (Carlsbad, Invitrogen) to outline cardiomyocyte membrane and TO-PRO-3 to visualize nuclei and area of infarction. Myocytes were measured in the border zone of the infarct and within the infarct using an outlining tool supplied by the Leica imaging software to measure area as mm 3 . An n=3 per group was measured.
Echocardiography and Analysis
Echocardiography was used to evaluate cardiac function after MI and injections using a Vevo 770 High-Resolution In-Vivo Imaging system. Mice during echocardiographic analysis were subjected to 1-2% isoflourane before assessing cardiac function. Infarct size was standardized by echocardiography performed on animals imaged along a parasternal short-axis view by Mmode recorded at two days post infarction/injection and successively for 4 weeks, then every other week up to 18 weeks. Functional recovery was determined by measurement of left ventricle (LV) anterior wall thickness during diastole in the area of the infarct and additionally averaged with the anterior wall thickness of the border zone where cells were delivered after surgery, or anterior wall dimension (AWD) as measured in millimeters (mm) for wall thinning. The percentage of akinetic wall was determined by parasternal short-axis view, and measured as the relative distance along the akinetic wall normalized to the total distance around the left ventricle * 100%. End diastolic diameter (EDD) and end systolic diameter (ESD) were measured in order to calculate LV fractional shortening (FS) and LV ejection fraction (EF). Hemodynamic performance assessed by echocardiography 2 days post-infarction was not statistically different between infarcted/injected groups (PBS, BMCe, and BMCeP).
Hemodynamics
Mice under chloral hydrate sedation were subjected to catheterization of the right carotid artery in order to enter the left ventricle of the heart. The catheter, a 1.2F PV-4.5mm Electrode, was supplied by Scisense (Ontario, Canada) and data acquisition and analysis was performed using LabScribe2 software, compatible with Scisense equipment. LabScribe2 software assisted in determining left ventricular volume and pressure measurements. Mice after catheterization were immediately subjected to heart retroperfusion.
RNA Isolation and Quantitative RT-PCR
RNA isolation from cells was performed according to the manufacturer's protocol from Zymo Research Corporation. RNA isolation from paraffin sections was performed using Recover All TM Total Nucleic Acid Isolation Kit (C/N AM1975, Life Technologies).
cDNA synthesis and quantitative RT-PCR
Reverse transcriptase was performed using the protocol described for iScript cDNA Synthesis Kit (BIORAD). cDNA was diluted 1:100 in nuclease free molecular grade water before performing qRT-PCR. cDNA was incubated with primers at 100nM concentration and IQ SYBR Green Supermix (BIORAD). qRT-PCR was run using an Opticon 2 machine and software.
Common Mouse Cytokine PCR Array RNA was extracted from BMCe and BMCeP according to the manufacturer's protocol from Zymo Research Corporation. 1ug was subjected to reverse transcriptase protocol using iScript cDNA Synthesis Kit (BIORAD). cDNA was diluted 1:100 in nuclease free molecular grade water before running on PCR array plate according the manufacturer's protocol from SA Biosciences (A Qiagen company), part number PAMM-021. B.
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